Dutasteride
Aliases
Avodart, Zytiga
9 clinical trials
4 products
1 abstract
3 indications
Indication
Prostate CancerIndication
Androgenetic AlopeciaIndication
Castrate-Sensitive Prostate CancerAbstract
A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC).Org: Froedtert & Medical College of Wisconsin, Department of Neurobiology and Anatomy,
Clinical trial
A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical ComorbiditiesStatus: Active (not recruiting), Estimated PCD: 2020-05-01
Clinical trial
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
Exploratory Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.Status: Active (not recruiting), Estimated PCD: 2024-04-29
Clinical trial
Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate CancerStatus: Completed, Estimated PCD: 2013-05-01
Clinical trial
Biomarker Study Targeting Abiraterone Metabolites and Polymporphisms in Men With PSA Progression on Abiraterone for the Treatment of Castration Resistant or Castration Sensitive Prostate Cancer (The Bio-STAMP Study)Status: Withdrawn, Estimated PCD: 2030-01-01
Clinical trial
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Product
DutasterideProduct
ADT alone